Safety Advantages Over HGH No IGF-1 elevation: Studies confirm AOD-9604 does not significantly increase insulin-like growth factor levels, removing the risk of acromegaly or abnormal growth Neutral glucose impact: Unlike HGH, it does not impair insulin sensitivity or worsen blood sugar regulation Clinical Evidence In a randomized controlled trial on obese subjects, AOD-9604 was well tolerated with no significant difference in adverse events compared to placebo AOD-9604 vs Other Weight Loss Therapeutics While AOD-9604 is unique as a peptide fragment of HGH, it sits within a broader landscape of weight loss interventions
Symptoms include abnormal redness on skin (like a sunburn) with tiny multiple sacs of fluids (vesicles) on the mouth, genitals, anal region, and buttocks
In any case, methyl B12 should convert to adenosyl B12 when needed
However, retatrutide shows a higher overall rate of side effects and produces a more pronounced dose-dependent increase in heart rate due to glucagon receptor activation
References For Further Reading (1) F Gorouhi and H I Maibach (2009) Role of topical peptides in preventing or treating aged skin -International Journal of Cosmetic Science, 2009 Oct, Volume 31 (Issue 5), Pages 327-45
